The European Medicines Agency has given marketing authorisation for a new formulation of Lumigan 0.01 per cent in the 27 member states of the European Union including the UK.
Lumigan 0.01 per cent is approved as first-line therapy for the reduction of elevated intraocular pressure in adults with chronic open-angle glaucoma and ocular hypertension. The new once-daily prescription eye drop is described by Allergan as delivering effective IOP-lowering results equivalent to those with Lumigan 0.03 per cent with improved tolerability. This is based on results from a multi-centre clinical trial where 373 patients with COAG or ocular hypertension were randomised for the two treatments over 12 months.
Treatment-related adverse events were significantly lower with the new formulation.